We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$701M
AUM Growth
+$112M
Cap. Flow
+$80.1M
Cap. Flow %
11.43%
Top 10 Hldgs %
45.26%
Holding
159
New
30
Increased
40
Reduced
26
Closed
28

Top Buys

Rank Stock Value
1
CEL
Cellcom Israel, Ltd.
CEL
+$14.1M
2
AGN
Allergan plc
AGN
+$14M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$9M
4
MRK icon
Merck
MRK
+$6.67M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$6.17M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$16M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.8M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.99M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.63M

Sector Composition

Rank Sector Weight
1 Healthcare 62.92%
2 Technology 5.67%
3 Communication Services 2.64%
4 Industrials 1.06%
5 Financials 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRNT icon
101
Kornit Digital
KRNT
$705M
$1.02M 0.15%
67,006
+9,706
+17% +$177K
NCNA
102
NuCana
NCNA
$5.49M
$919K 0.13%
+10
New +$863K
ARAV
103
DELISTED
Aravive, Inc. Common Stock
ARAV
$802K 0.11%
54,587
-8,334
-13% -$841K
VRSK icon
104
Verisk Analytics
VRSK
$25.4B
$782K 0.11%
9,400
– –
RCKT icon
105
Rocket Pharmaceuticals
RCKT
$340M
$715K 0.1%
100,441
– –
GNCA
106
DELISTED
Genocea Biosciences, Inc.
GNCA
$715K 0.1%
61,250
– –
XENE icon
107
Xenon Pharmaceuticals
XENE
$6.06B
$673K 0.1%
228,029
– –
ATXS
108
DELISTED
Astria Therapeutics
ATXS
$611K 0.09%
4,801
– –
VKTX icon
109
Viking Therapeutics
VKTX
$3.7B
$554K 0.08%
+290,000
New +$329K
CSTE icon
110
Caesarstone
CSTE
$72.3M
$531K 0.08%
17,833
-104,964
-85% -$3.28M
TJX icon
111
TJX Companies
TJX
$174B
$428K 0.06%
11,600
-37,800
-77% -$1.35M
UNH icon
112
UnitedHealth
UNH
$376B
$392K 0.06%
2,000
– –
SAGE
113
DELISTED
Sage Therapeutics
SAGE
$381K 0.05%
6,118
+1,118
+22% +$87.8K
TMX
114
DELISTED
Terminix Global Holdings, Inc.
TMX
$374K 0.05%
11,944
+4,479
+60% +$132K
ORLY icon
115
O'Reilly Automotive
ORLY
$72.9B
$366K 0.05%
+25,500
New +$337K
WSO icon
116
Watsco Inc
WSO
$12.7B
$338K 0.05%
2,100
– –
MHK icon
117
Mohawk Industries
MHK
$7.5B
$272K 0.04%
1,100
– –
AAP icon
118
Advance Auto Parts
AAP
$3.35B
$266K 0.04%
+2,686
New +$271K
ECL icon
119
Ecolab
ECL
$78.1B
$257K 0.04%
2,000
+1,000
+100% +$131K
VIRX
120
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$217K 0.03%
3,193
-2,327
-42% -$190K
LOW icon
121
Lowe's Companies
LOW
$117B
$208K 0.03%
2,600
– –
SEE
122
DELISTED
Sealed Air
SEE
$192K 0.03%
4,500
– –
LVNTA
123
DELISTED
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
$173K 0.02%
3,000
– –
TRIP icon
124
TripAdvisor
TRIP
$1.65B
$162K 0.02%
4,000
– –
ULTI
125
DELISTED
Ultimate Software Group Inc
ULTI
$152K 0.02%
800
– –
3 4
5
6 7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sphera Funds Management held 159 positions worth $701M, up 19% from $589M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $80.1M of net new capital in Q3 2017, opening 30 new positions and adding to 40 existing holdings. Its largest new stake was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Caesarstone, an estimated $3.28M trimmed.

  • Sphera Funds Management's largest Q3 2017 buy was Cellcom Israel, Ltd.: 1,535,988 shares worth $14.3M.
  • Sphera Funds Management added most to Merck in Q3 2017, an estimated $6.67M increase.
  • Sphera Funds Management's biggest Q3 2017 reduction was Caesarstone, cutting an estimated $3.28M.
  • Sphera Funds Management fully exited Novartis in Q3 2017, selling an estimated $16M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $701M portfolio in Q3 2017.
  • Sphera Funds Management opened 30 new positions and closed 28 in Q3 2017.
  • Sphera Funds Management's portfolio value rose 19% quarter-over-quarter to $701M.

Based on Sphera Funds Management's 13F filing for Q3 2017, filed 9 Nov 2017.